MedTrace Logo

A Study to Develop Molecular Integrated Predictive Models of Breast Radio-toxicity (Precise-RTox)

NCT06114589 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 420

Last updated 2023-11-07

No results posted yet for this study

Summary

Breast radiation treatment is burdened by acute and chronic toxicities, in most cases mild. However, considering the excellent life expectancy of patients with breast cancer, maintaining a low toxicity profile is of primary importance in order to guarantee a satisfactory quality of life. The definition of the molecular and genetic variables related to radiotoxicity and their integration into predictive molecular signatures may allow the risk of toxicity to be individualized. This would provide the clinician with a useful tool in order to personalize the radiation treatment, thus being able to choose the best technique or schedule for each patient.

Conditions

Sponsors & Collaborators

  • Centro di Riferimento Oncologico - Aviano

    lead OTHER

Principal Investigators

  • Lorenzo Vinante, MD · Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS

  • Barbara Belletti, PhD · Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-25
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06114589 on ClinicalTrials.gov